Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 6 studies | 22% ± 10% | |
epithelial cell | 5 studies | 33% ± 14% | |
CD4-positive, alpha-beta T cell | 4 studies | 20% ± 1% | |
CD8-positive, alpha-beta T cell | 4 studies | 19% ± 2% | |
B cell | 3 studies | 23% ± 3% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 16% ± 1% | |
hematopoietic precursor cell | 3 studies | 25% ± 7% | |
non-classical monocyte | 3 studies | 22% ± 4% | |
ciliated cell | 3 studies | 26% ± 2% | |
dendritic cell | 3 studies | 34% ± 6% | |
natural killer cell | 3 studies | 20% ± 1% | |
basal cell | 3 studies | 29% ± 9% | |
plasmacytoid dendritic cell | 3 studies | 22% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 3 studies | 22% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 884.45 | 1445 / 1445 | 100% | 40.72 | 183 / 183 |
liver | 100% | 1266.51 | 226 / 226 | 100% | 66.14 | 406 / 406 |
ovary | 100% | 548.37 | 180 / 180 | 100% | 48.43 | 430 / 430 |
pancreas | 100% | 1135.50 | 328 / 328 | 100% | 51.87 | 178 / 178 |
stomach | 100% | 801.05 | 359 / 359 | 100% | 56.36 | 286 / 286 |
uterus | 100% | 681.89 | 170 / 170 | 100% | 85.42 | 459 / 459 |
bladder | 100% | 818.24 | 21 / 21 | 100% | 73.13 | 503 / 504 |
skin | 100% | 1897.63 | 1809 / 1809 | 100% | 64.14 | 471 / 472 |
breast | 100% | 998.26 | 459 / 459 | 100% | 69.88 | 1114 / 1118 |
intestine | 100% | 868.52 | 966 / 966 | 100% | 64.83 | 525 / 527 |
prostate | 100% | 982.82 | 245 / 245 | 100% | 63.58 | 500 / 502 |
kidney | 100% | 821.65 | 89 / 89 | 100% | 46.24 | 897 / 901 |
thymus | 100% | 670.04 | 651 / 653 | 100% | 51.25 | 604 / 605 |
lung | 99% | 811.00 | 574 / 578 | 100% | 62.74 | 1155 / 1155 |
brain | 99% | 611.13 | 2620 / 2642 | 100% | 57.24 | 705 / 705 |
adrenal gland | 100% | 1241.14 | 258 / 258 | 99% | 45.58 | 227 / 230 |
adipose | 100% | 1023.78 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 101.14 | 29 / 29 |
muscle | 100% | 1470.88 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 859.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 70.73 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 81.43 | 1 / 1 |
blood vessel | 100% | 726.82 | 1330 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 553.79 | 842 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 39.34 | 77 / 80 |
peripheral blood | 64% | 718.35 | 590 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0097035 | Biological process | regulation of membrane lipid distribution |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0015914 | Biological process | phospholipid transport |
GO_0034644 | Biological process | cellular response to UV |
GO_0090201 | Biological process | negative regulation of release of cytochrome c from mitochondria |
GO_0120009 | Biological process | intermembrane lipid transfer |
GO_2001140 | Biological process | positive regulation of phospholipid transport |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045332 | Biological process | phospholipid translocation |
GO_1902166 | Biological process | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
GO_0006977 | Biological process | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
GO_0006915 | Biological process | apoptotic process |
GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
GO_0005739 | Cellular component | mitochondrion |
GO_0005758 | Cellular component | mitochondrial intermembrane space |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0002039 | Molecular function | p53 binding |
GO_1990050 | Molecular function | phosphatidic acid transfer activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TRIAP1 |
Protein name | TP53-regulated inhibitor of apoptosis 1 (Protein 15E1.1) (WF-1) (p53-inducible cell-survival factor) (p53CSV) |
Synonyms | 15E1.1 HSPC132 |
Description | FUNCTION: Involved in the modulation of the mitochondrial apoptotic pathway by ensuring the accumulation of cardiolipin (CL) in mitochondrial membranes. In vitro, the TRIAP1:PRELID1 complex mediates the transfer of phosphatidic acid (PA) between liposomes and probably functions as a PA transporter across the mitochondrion intermembrane space to provide PA for CL synthesis in the inner membrane . Likewise, the TRIAP1:PRELID3A complex mediates the transfer of phosphatidic acid (PA) between liposomes (in vitro) and probably functions as a PA transporter across the mitochondrion intermembrane space (in vivo) . Mediates cell survival by inhibiting activation of caspase-9 which prevents induction of apoptosis . . |
Accessions | ENST00000546954.2 O43715 |